ATU iHub client company NUA Surgical has announced a significant milestone in its journey to improve maternal healthcare, with the first infants successfully delivered using its innovative SteriCISION® C-Section Retractor during a clinical investigation.
Photo credit: Andrew Downes
The Galway-based MedTech company, headquartered at ATU iHub, has developed the SteriCISION® C-Section Retractor to address key challenges faced during Caesarean deliveries. The device is designed to improve surgical access, visibility and ergonomics for clinicians while helping to reduce factors that can contribute to complications during surgery.
The first clinical investigation involved five patients at Hospital Santo Tomás Querétaro in Panama, where five infants were successfully delivered using the device. The study met its primary endpoints, demonstrating the technical feasibility of the SteriCISION® Retractor while maintaining surgical access and visualisation throughout the procedures.
NUA Surgical has rapidly established itself as a leading innovator in women’s health, attracting international recognition and investment for its work in advancing maternal care.
This achievement represents an important step towards the commercialisation of the SteriCISION® C-Section Retractor and highlights the potential for homegrown innovation to address critical healthcare challenges on a global scale. With more than 30 million Caesarean sections performed worldwide each year, advancements that improve surgical safety and outcomes have the potential to benefit mothers, babies and healthcare professionals alike.
The milestone also reflects the world-class innovation environment fostered within the ATU iHub community, where ambitious companies are supported to develop breakthrough technologies with international impact.
Congratulations to the entire NUA Surgical team on this remarkable achievement and on reaching such an important stage in their mission to improve maternal health around the world.
Innovations that enhance safety, access and outcomes have the potential to make a significant impact on maternal healthcare.
The milestone also highlights the calibre of innovation being developed within the ATU iHub ecosystem. NUA Surgical’s progress from early-stage concept development to achieving successful first-in-human clinical use demonstrates how world-class innovation, entrepreneurship and clinical expertise can come together to address critical healthcare challenges.
Everyone at ATU iHub congratulates the NUA Surgical team on this outstanding achievement and looks forward to supporting the company as it continues its journey towards commercialisation and improving outcomes for mothers and babies worldwide.